RCM
DMAAR

Radcliffe Capital Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Radcliffe Capital Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3K Sell
231,551
-93,549
-29% -$9.91K ﹤0.01% 391
2025
Q4 		$56.5K Hold
325,100
– – ﹤0.01% 265
2025
Q3 		$3.34M Buy
+325,100
New +$60.4K 0.21% 110

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Radcliffe Capital Management's DMAAR Position: Q1 2026 in Review

Radcliffe Capital Management reduced its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 29% in Q1 2026, selling an estimated $9.91K and leaving 231,551 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #391.

Radcliffe Capital Management first reported a position in DMAAR in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.34M in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Radcliffe Capital Management held 231,551 shares of Drugs Made In America Acquisition Corp Rights worth $13.3K as of Q1 2026.
  • Radcliffe Capital Management sold 93,549 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $9.91K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Radcliffe Capital Management's portfolio in Q1 2026, its #391 holding.
  • Radcliffe Capital Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 3 quarters since.
  • Radcliffe Capital Management's Drugs Made In America Acquisition Corp Rights position peaked at $3.34M in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Radcliffe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.